VOYAGER THERAPEUTICS INC (VYGR)
US92915B1061 - Common Stock
We assign a fundamental rating of 5 out of 10 to VYGR. VYGR was compared to 571 industry peers in the Biotechnology industry. While VYGR has a great health rating, its profitability is only average at the moment. While showing a medium growth rate, VYGR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year VYGR was profitable.
VYGR had a negative operating cash flow in the past year.
In multiple years VYGR reported negative net income over the last 5 years.
In multiple years VYGR reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.07%, VYGR belongs to the top of the industry, outperforming 95.94% of the companies in the same industry.
Looking at the Return On Equity, with a value of 7.84%, VYGR belongs to the top of the industry, outperforming 95.41% of the companies in the same industry.
With an excellent Return On Invested Capital value of 2.46%, VYGR belongs to the best of the industry, outperforming 94.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 7.84% | ||
| ROIC | 2.46% |
ROA(3y)-9.39%
ROA(5y)-5.28%
ROE(3y)-32.51%
ROE(5y)-23.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 15.80%, VYGR belongs to the best of the industry, outperforming 96.47% of the companies in the same industry.
In the last couple of years the Profit Margin of VYGR has grown nicely.
The Operating Margin of VYGR (7.25%) is better than 94.71% of its industry peers.
In the last couple of years the Operating Margin of VYGR has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.25% | ||
| PM (TTM) | 15.8% | ||
| GM | N/A |
OM growth 3Y44.98%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VYGR is destroying value.
VYGR has more shares outstanding than it did 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.38 indicates that VYGR is not a great score, but indicates only limited risk for bankruptcy at the moment.
VYGR's Altman-Z score of 2.38 is fine compared to the rest of the industry. VYGR outperforms 72.84% of its industry peers.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.38 |
ROIC/WACC0.23
WACC10.49%
2.3 Liquidity
VYGR has a Current Ratio of 8.45. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a better Current ratio (8.45) than 74.96% of its industry peers.
A Quick Ratio of 8.45 indicates that VYGR has no problem at all paying its short term obligations.
VYGR has a Quick ratio of 8.45. This is in the better half of the industry: VYGR outperforms 75.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.45 | ||
| Quick Ratio | 8.45 |
3. Growth
3.1 Past
VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.28%.
The Earnings Per Share has been growing by 48.16% on average over the past years. This is a very strong growth
Looking at the last year, VYGR shows a small growth in Revenue. The Revenue has grown by 3.33% in the last year.
VYGR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 101.11% yearly.
EPS 1Y (TTM)-42.28%
EPS 3Y48.16%
EPS 5YN/A
EPS Q2Q%72.88%
Revenue 1Y (TTM)3.33%
Revenue growth 3Y13.48%
Revenue growth 5Y101.11%
Sales Q2Q%433.79%
3.2 Future
VYGR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.20% yearly.
VYGR is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.05% yearly.
EPS Next Y-143.36%
EPS Next 2Y-59.79%
EPS Next 3Y-35.07%
EPS Next 5Y-15.2%
Revenue Next Year-56.7%
Revenue Next 2Y-38.66%
Revenue Next 3Y-26.16%
Revenue Next 5Y-11.05%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.96, the valuation of VYGR can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of VYGR indicates a rather cheap valuation: VYGR is cheaper than 98.59% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.29, VYGR is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.96 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -15.9 |
4.3 Compensation for Growth
VYGR has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as VYGR's earnings are expected to decrease with -35.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-59.79%
EPS Next 3Y-35.07%
5. Dividend
5.1 Amount
VYGR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VOYAGER THERAPEUTICS INC
NASDAQ:VYGR (11/22/2024, 8:12:46 PM)
Premarket: 5.63 -0.03 (-0.44%)5.655
+0.23 (+4.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap308.93M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.96 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 7.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 7.25% | ||
| PM (TTM) | 15.8% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.45 | ||
| Quick Ratio | 8.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-42.28%
EPS 3Y48.16%
EPS 5Y
EPS Q2Q%
EPS Next Y-143.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.33%
Revenue growth 3Y13.48%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y